SciELO - Scientific Electronic Library Online

 
vol.29 número1Metástasis hepáticas de cáncer de colon: Nuevos enfoques terapéuticos. Quimioterapia neoadyuvanteValor pronóstico de las alteraciones inmunológicas cuantitativas en los pacientes con melanoma índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Oncología (Barcelona)

versión impresa ISSN 0378-4835

Resumen

ALES MARTINEZ, J. E.. Chemoprevention of breast cancer. Oncología (Barc.) [online]. 2006, vol.29, n.1, pp.24-29. ISSN 0378-4835.

The pharmacological prevention (chemoprevention) of breast cancer is the new challenge of modern medical oncology to deal with a kind of tumor that is the most frequent among the female population all over the world. The extension of the screening programs for early-stage detection and the advances in therapeutic pharmacology have achieved a continued reduction in breast cancer mortality in the last decade. However, the incidence rate continues increasing or is at least stable, what considered together with the increasing proportion of women in follow-up after completing the adjuvant treatment, leads to a continued increase of the medical and social burden of breast cancer. For this reason, the securing of an efficacious, safe and tolerated drug diminishing the tumor incidence is a very desirable objective. Presently, once demonstrated that tamoxifen-mediated estrogenic inhibition can prevent the appearance of breast cancer, the research of the role of other SERMs (Selective Estrogen Receptor Modulators) and aromatase inhibitors is very active, looking for products having a favorable risk-benefit ratio that will make then useful for wide groups of population.

Palabras clave : Chemoprevention; Breast cancer; Tamoxifen; SERMs; Exemestane; ExCel; Anastrozol.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons